Trio of pharma companies jump after CDC confirms U.S. Ebola case
NEW YORK, Sept 30 (Reuters) - Several pharmaceutical companies with potential Ebola treatments jumped in extended trade on Tuesday after the U.S. Centers for Disease Control and Prevention confirmed the first case of the virus diagnosed in the country.
U.S.-listed shares of Tekmira Pharmaceuticals jumped 20.6 percent to $25.50, BioCryst Pharmaceuticals surged 14.5 percent to $11.20 while Sarepta Therapeutics climbed 8.2 percent to $22.83. (Reporting by Chuck Mikolajczak; Editing by Chris Reese)
© Thomson Reuters 2017 All rights reserved.